본문으로 건너뛰기
← 뒤로

[Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome].

1/5 보강
Recenti progressi in medicina 2026 Vol.117(2) p. e29-e32 OA
Retraction 확인
출처

Casadei B, Zinzani PL

📝 환자 설명용 한 줄

CAR-T cell therapy has revolutionized second-line treatment for patients with refractory/relapsed large B-cell lymphoma within 12 months, demonstrating clear superiority in terms of both response rate

이 논문을 인용하기

↓ .bib ↓ .ris
APA Casadei B, Zinzani PL (2026). [Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome].. Recenti progressi in medicina, 117(2), e29-e32. https://doi.org/10.1701/4649.46632
MLA Casadei B, et al.. "[Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome].." Recenti progressi in medicina, vol. 117, no. 2, 2026, pp. e29-e32.
PMID 41716106 ↗
DOI 10.1701/4649.46632

Abstract

CAR-T cell therapy has revolutionized second-line treatment for patients with refractory/relapsed large B-cell lymphoma within 12 months, demonstrating clear superiority in terms of both response rate and survival compared to salvage chemotherapy followed by autologous stem cell transplantation (auto-SCT). In this setting, CAR-T therapy also appears to overcome the poor prognosis associated with a diagnosis of high-grade B-cell lymphoma (HGBCL), as demonstrated by both clinical studies and real-world data, changing the outcome for a population of patients who would otherwise have no valid therapeutic alternatives. The diagnosis of HGBCL and a lack of complete response to interim re-evaluation during first-line therapy should lead to a CAR-T program, allowing for early referral and therefore rapid access to this cell therapy, impacting the outcome of the therapy itself.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기